title: [Current topics over updating guidelines on the management and treatment of glucocorticoid-induced osteoporosis].
abstract: Glucocorticoids (GCs) were widely used for the treatment of various disorders. Since GC-induced bone loss is most rapid during the initial 3 - 6 months and primary prevention of bone loss is especially important, guidelines for management of GC-induced osteoporosis have been published overseas and in Japan. In response to changes in the circumstances surrounding GIO regarding fracture assessment tool and drug therapy, ACR revised recommendations incorporated FRAX®, the WHO fracture risk assessment tool and the Japanese Society of Bone and Mineral Research have finished revision work of the guidelines and the updated guideline will be published soon.
authors.affiliation: Division of Rheumatology, Tokai University School of Medicine, Japan.
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Suzuki
mesh_terms: D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D005598:Fractures, Spontaneous / Q000139:chemically induced / Q000517:prevention & control; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D010024:Osteoporosis / Q000139:chemically induced* / Q000517:prevention & control*; D017410:Practice Guidelines as Topic; D011239:Prednisolone / Q000009:adverse effects*; D018570:Risk Assessment / Q000379:methods; D019379:Teriparatide / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D005938:Glucocorticoids; D019379:Teriparatide; D011239:Prednisolone